Marinus Pharmaceuticals, Inc. MRNS
Set alert
0.55 0.00 0.00%
At close · Feb 10
0.5492 Day range 0.55
52-week range unavailable
- YTD
- +2.78%
- 1 year
- -94.49%
- Open
- 0.5492
- Prev close
- 0.55
- Mkt cap
- 13.13M
- Vol
- 1.10M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5492
- High
- 0.55
- Forward P/E
- -0.34
- Beta
- 1.26
- Short ratio
- 1.09
- Inst. own
- 83.04%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.5705
- 200-d avg
- 2.12
- 1y target
- 1.47
Analyst view
Consensus: none
Price target (mean) 1.47 +166.7% upside
Now 0.55
- Target (low)
- 0.30
- Target (mean)
- 1.47
- Target (high)
- 3.00
Ratings (0m) 9 2 buy · 7 hold · 0 sell
- Strong buy0
- Buy2
- Hold7
- Sell0
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 10
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.285 | -0.33 – -0.24 | -0.8074 | +64.7% | 10.33M | +43.7% | 4 |
| Next quarter | -0.18 | -0.30 – -0.06 | -0.68 | +73.5% | 10.48M | +36.5% | 2 |
| Current year | -2.00 | -2.04 – -1.97 | -2.70 | +26.0% | 34.77M | +12.2% | 4 |
| Next year | -0.72 | -1.30 – -0.24 | -2.00 | +64.0% | 50.73M | +45.9% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Nov 14, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Oct 25, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Oct 25, 2024 | TD Cowen | Downgrade | Buy | Hold |
| Oct 25, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Oct 25, 2024 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 25, 2024 | Jefferies | Downgrade | Buy | Hold |
| Oct 24, 2024 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Oct 24, 2024 | EF Hutton | Maintained | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 14, 2024 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Jun 18, 2024 | Truist Securities | Maintained | Buy | Buy |
| Jun 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 17, 2024 | Truist Securities | Maintained | Buy | Buy |
| Apr 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 16, 2024 | Baird | Downgrade | Outperform | Neutral |
| Apr 15, 2024 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Apr 10, 2024 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Mar 26, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 5, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 8, 2023 | Truist Securities | Maintained | Buy | Buy |
| Sep 21, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 20, 2023 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 20, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 11, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 11, 2023 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 11, 2023 | Truist Securities | Maintained | Buy | Buy |
| Aug 11, 2023 | Ladenburg Thalmann | Maintained | Buy | Buy |